# Core 3: Bioinformatics and Biostatistics Core

> **NIH NIH P01** · EMORY UNIVERSITY · 2023 · $254,864

## Abstract

SUMMARY
The Emory Lung Cancer P01 application aims to decipher the underlying mechanisms of immunotherapy
resistance of LKB1-mut lung cancer and to seek possible therapeutic solutions with three interconnected projects
to address this urgent unmet medical need. The function of the Bioinformatics and Biostatistics Core (Core
3) is to provide robust and transparent analytic strategies, sophisticated and integrated data analysis and
management platforms, and state-of-the-art methodologies to maximize the success of the overall program
through guiding and fostering data-driven interactions and collaborations. To support this goal, our Core 3 team
of investigators has complementary expertise and extensive experience in biostatistics, bioinformatics, and
medical informatics and data management that is critical for rigorous experimental design and streamlined data
analysis, interpretation, sharing and management for basic mechanism-driven examination and clinical studies.
Specifically, we will (i) provide comprehensive biostatistical expertise and resources in support to Lung Cancer
P01 projects, including novel clinical trial design; (ii) provide a new integrative computational platform to support
the elucidation of the molecular basis for GDH1 (Project 1), IAP/STING (Project 2), and FAK (Project 3)-
dependent tumorigenesis in LKB1-deficient lung cancer with project leaders; and (iii) develop and maintain a
centralized data acquisition and management system that is customized explicitly for this P01. Core 3 serves as
a focal point of the P01 to ensure data integrity, scientific rigor, and sharing; and to foster collaborations between
projects based on integrated analysis of mechanistic and clinical results and close interactions with each project
and Core 1 and Core 2 through a shared database. Serving as a critical component of the P01 Program, Core
3 will be critical to further safeguard and elevate the entire research quality in this P01 to support the development
of the next generation of effective anticancer immunity-based therapeutic strategies for patients with LKB1
mutated lung cancer.

## Key facts

- **NIH application ID:** 10631168
- **Project number:** 5P01CA257906-02
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Yuan Liu
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $254,864
- **Award type:** 5
- **Project period:** 2022-06-01 → 2027-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10631168

## Citation

> US National Institutes of Health, RePORTER application 10631168, Core 3: Bioinformatics and Biostatistics Core (5P01CA257906-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10631168. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*